Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment
{{output}}
Non-muscle-invasive bladder cancer (NMIBC) carries 70% incidence yet remains plagued by high recurrence because single-modality chemotherapy or immunotherapy is crippled by rapid urinary clearance, poor tumor specificity, and narrow therapeutic windows. To ove... ...
